Ivabrad OD 15 Tablet PR contains Ivabradine 15 mg, a selective inhibitor of the cardiac pacemaker If current, which plays a crucial role in regulating heart rate. It is primarily indicated for the treatment of chronic stable angina pectoris in patients with normal sinus rhythm who are intolerant to or inadequately controlled by beta-blockers, as well as for symptomatic management of chronic heart failure with reduced ejection fraction in patients who remain tachycardic despite optimal standard therapy. Ivabradine acts by specifically reducing the heart rate without affecting myocardial contractility or ventricular repolarization, thereby improving myocardial oxygen supply-demand balance and reducing angina symptoms. The prolonged-release formulation allows once-daily dosing, enhancing patient compliance. Ivabrad OD 15 Tablet PR should be administered under medical supervision with careful monitoring of heart rate and rhythm, and dose adjustments may be necessary based on therapeutic response and tolerability. It is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick sinus syndrome, sinoatrial block, or third-degree atrioventricular block in the absence of a pacemaker. Common adverse effects include bradycardia, luminous phenomena, and dizziness. Caution is advised when used concomitantly with other heart rate-lowering agents.